Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7609
Submission : 1988-08-02
Status :
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2025-07-15
Valid Till : 2028-07-07
Written Confirmation Number : WC-0067
Address of the Firm : Chemical Technical Operation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
Lead Product(s) :
Alemtuzumab,Glatiramer Acetate,Interferon Beta,Methylprednisolone,Ranitidine,Cetirizine,Dexchloropheniramine Maleate,Paracetamol,Acyclovir,
Therapeutic Area :
Neurology Highest Development Status :
Phase III Partner/Sponsor/Collaborator :
Undisclosed Deal Size : Inapplicable Deal Type : Inapplicable
Details : Alemtuzumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 11, 2017
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.
CAS Number : 2224-52-4
End Use API : Glatiramer Acetate
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.
CAS Number : 1676-74-0
End Use API : Glatiramer Acetate
About The Company : PMC Isochem is a CDMO company acquired by PMC International in 2017. It manufactures cGMP intermediates, active pharmaceutical ingredients and functional excipi...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - FOR SOLUTION;SUBCUTANEOUS - 20MG/VIA...DOSAGE - FOR SOLUTION;SUBCUTANEOUS - 20MG/VIAL
USFDA APPLICATION NUMBER - 20622
DOSAGE - INJECTABLE;SUBCUTANEOUS - 40MG/ML
USFDA APPLICATION NUMBER - 20622
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Chewable & Orodispersible Aids
Taste Masking
Direct Compression
Disintegrants & Superdisintegrants
Parenteral
Granulation
Co-Processed Excipients
Solubilizers
Thickeners and Stabilizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
52
PharmaCompass offers a list of Glatiramer Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Glatiramer Acetate manufacturer or Glatiramer Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Glatiramer Acetate manufacturer or Glatiramer Acetate supplier.
PharmaCompass also assists you with knowing the Glatiramer Acetate API Price utilized in the formulation of products. Glatiramer Acetate API Price is not always fixed or binding as the Glatiramer Acetate Price is obtained through a variety of data sources. The Glatiramer Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Synthetic Peptide Copolymer I manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Synthetic Peptide Copolymer I, including repackagers and relabelers. The FDA regulates Synthetic Peptide Copolymer I manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Synthetic Peptide Copolymer I API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Synthetic Peptide Copolymer I manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Synthetic Peptide Copolymer I supplier is an individual or a company that provides Synthetic Peptide Copolymer I active pharmaceutical ingredient (API) or Synthetic Peptide Copolymer I finished formulations upon request. The Synthetic Peptide Copolymer I suppliers may include Synthetic Peptide Copolymer I API manufacturers, exporters, distributors and traders.
click here to find a list of Synthetic Peptide Copolymer I suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Synthetic Peptide Copolymer I DMF (Drug Master File) is a document detailing the whole manufacturing process of Synthetic Peptide Copolymer I active pharmaceutical ingredient (API) in detail. Different forms of Synthetic Peptide Copolymer I DMFs exist exist since differing nations have different regulations, such as Synthetic Peptide Copolymer I USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Synthetic Peptide Copolymer I DMF submitted to regulatory agencies in the US is known as a USDMF. Synthetic Peptide Copolymer I USDMF includes data on Synthetic Peptide Copolymer I's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Synthetic Peptide Copolymer I USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Synthetic Peptide Copolymer I suppliers with USDMF on PharmaCompass.
A Synthetic Peptide Copolymer I written confirmation (Synthetic Peptide Copolymer I WC) is an official document issued by a regulatory agency to a Synthetic Peptide Copolymer I manufacturer, verifying that the manufacturing facility of a Synthetic Peptide Copolymer I active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Synthetic Peptide Copolymer I APIs or Synthetic Peptide Copolymer I finished pharmaceutical products to another nation, regulatory agencies frequently require a Synthetic Peptide Copolymer I WC (written confirmation) as part of the regulatory process.
click here to find a list of Synthetic Peptide Copolymer I suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Synthetic Peptide Copolymer I as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Synthetic Peptide Copolymer I API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Synthetic Peptide Copolymer I as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Synthetic Peptide Copolymer I and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Synthetic Peptide Copolymer I NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Synthetic Peptide Copolymer I suppliers with NDC on PharmaCompass.
Synthetic Peptide Copolymer I Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Synthetic Peptide Copolymer I GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Synthetic Peptide Copolymer I GMP manufacturer or Synthetic Peptide Copolymer I GMP API supplier for your needs.
A Synthetic Peptide Copolymer I CoA (Certificate of Analysis) is a formal document that attests to Synthetic Peptide Copolymer I's compliance with Synthetic Peptide Copolymer I specifications and serves as a tool for batch-level quality control.
Synthetic Peptide Copolymer I CoA mostly includes findings from lab analyses of a specific batch. For each Synthetic Peptide Copolymer I CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Synthetic Peptide Copolymer I may be tested according to a variety of international standards, such as European Pharmacopoeia (Synthetic Peptide Copolymer I EP), Synthetic Peptide Copolymer I JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Synthetic Peptide Copolymer I USP).
